• Je něco špatně v tomto záznamu ?

Effect of substituents at the C3 ́, C3 ́N, C10 and C2-meta-benzoate positions of taxane derivatives on their activity against resistant cancer cells

P. Daniel, K. Balušíková, J. Truksa, J. Černý, M. Jaček, M. Jelínek, MJV. Mulenga, K. Voráčová, L. Chen, L. Wei, Y. Sun, I. Ojima, J. Kovář

. 2024 ; 489 (-) : 116993. [pub] 20240612

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019538

Grantová podpora
R01 CA103314 NCI NIH HHS - United States

We tested the effect of substituents at the (1) C3 ́, C3 ́N, (2) C10, and (3) C2-meta-benzoate positions of taxane derivatives on their activity against sensitive versus counterpart paclitaxel-resistant breast (MCF-7) and ovarian (SK-OV-3) cancer cells. We found that (1) non-aromatic groups at both C3 ́ and C3 ́N positions, when compared with phenyl groups at the same positions of a taxane derivative, significantly reduced the resistance of ABCB1 expressing MCF-7/PacR and SK-OV-3/PacR cancer cells. This is, at least in the case of the SB-T-1216 series, accompanied by an ineffective decrease of intracellular levels in MCF-7/PacR cells. The low binding affinity of SB-T-1216 in the ABCB1 binding cavity can elucidate these effects. (2) Cyclopropanecarbonyl group at the C10 position, when compared with the H atom, seems to increase the potency and capability of the derivative in overcoming paclitaxel resistance in both models. (3) Derivatives with fluorine and methyl substituents at the C2-meta-benzoate position were variously potent against sensitive and resistant cancer cells. All C2 derivatives were less capable of overcoming acquired resistance to paclitaxel in vitro than non-substituted analogs. Notably, fluorine derivatives SB-T-121205 and 121,206 were more potent against sensitive and resistant SK-OV-3 cells, and derivatives SB-T-121405 and 121,406 were more potent against sensitive and resistant MCF-7 cells. (4) The various structure-activity relationships of SB-T derivatives observed in two cell line models known to express ABCB1 favor their complex interaction not based solely on ABCB1.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019538
003      
CZ-PrNML
005      
20241024110807.0
007      
ta
008      
241015e20240612xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.taap.2024.116993 $2 doi
035    __
$a (PubMed)38870637
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Daniel, Petr $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: petr.daniel@lf3.cuni.cz
245    10
$a Effect of substituents at the C3 ́, C3 ́N, C10 and C2-meta-benzoate positions of taxane derivatives on their activity against resistant cancer cells / $c P. Daniel, K. Balušíková, J. Truksa, J. Černý, M. Jaček, M. Jelínek, MJV. Mulenga, K. Voráčová, L. Chen, L. Wei, Y. Sun, I. Ojima, J. Kovář
520    9_
$a We tested the effect of substituents at the (1) C3 ́, C3 ́N, (2) C10, and (3) C2-meta-benzoate positions of taxane derivatives on their activity against sensitive versus counterpart paclitaxel-resistant breast (MCF-7) and ovarian (SK-OV-3) cancer cells. We found that (1) non-aromatic groups at both C3 ́ and C3 ́N positions, when compared with phenyl groups at the same positions of a taxane derivative, significantly reduced the resistance of ABCB1 expressing MCF-7/PacR and SK-OV-3/PacR cancer cells. This is, at least in the case of the SB-T-1216 series, accompanied by an ineffective decrease of intracellular levels in MCF-7/PacR cells. The low binding affinity of SB-T-1216 in the ABCB1 binding cavity can elucidate these effects. (2) Cyclopropanecarbonyl group at the C10 position, when compared with the H atom, seems to increase the potency and capability of the derivative in overcoming paclitaxel resistance in both models. (3) Derivatives with fluorine and methyl substituents at the C2-meta-benzoate position were variously potent against sensitive and resistant cancer cells. All C2 derivatives were less capable of overcoming acquired resistance to paclitaxel in vitro than non-substituted analogs. Notably, fluorine derivatives SB-T-121205 and 121,206 were more potent against sensitive and resistant SK-OV-3 cells, and derivatives SB-T-121405 and 121,406 were more potent against sensitive and resistant MCF-7 cells. (4) The various structure-activity relationships of SB-T derivatives observed in two cell line models known to express ABCB1 favor their complex interaction not based solely on ABCB1.
650    _2
$a lidé $7 D006801
650    12
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a MFC-7 buňky $7 D061986
650    12
$a P-glykoproteiny $x metabolismus $x genetika $7 D018435
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a taxoidy $x farmakologie $x chemie $7 D043823
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a paclitaxel $x farmakologie $7 D017239
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a nádory prsu $x farmakoterapie $x patologie $7 D001943
650    _2
$a antitumorózní látky $x farmakologie $x chemie $7 D000970
650    _2
$a benzoáty $x farmakologie $x chemie $7 D001565
650    _2
$a nádory vaječníků $x farmakoterapie $x patologie $7 D010051
655    _2
$a časopisecké články $7 D016428
700    1_
$a Balušíková, Kamila $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Truksa, Jaroslav $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic; Laboratory of Tumor Resistance, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Centre, Vestec, Czech Republic
700    1_
$a Černý, Jiří $u Laboratory of Structural Bioinformatics of Proteins, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Centre, Vestec, Czech Republic
700    1_
$a Jaček, Martin $u Department of Hygiene, Epidemiology and Preventive Medicine, Third Faculty of Medicine, Charles Univesity, Prague, Czech Republic
700    1_
$a Jelínek, Michael $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Mulenga, Mutale Jane Vobruba $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Voráčová, Kateřina $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Chen, Lei $u Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY, USA
700    1_
$a Wei, Longfei $u Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY, USA
700    1_
$a Sun, Yi $u Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY, USA
700    1_
$a Ojima, Iwao $u Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY, USA
700    1_
$a Kovář, Jan $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: jan.kovar@lf3.cuni.cz
773    0_
$w MED00010691 $t Toxicology and applied pharmacology $x 1096-0333 $g Roč. 489 (20240612), s. 116993
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38870637 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110801 $b ABA008
999    __
$a ok $b bmc $g 2202021 $s 1231511
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 489 $c - $d 116993 $e 20240612 $i 1096-0333 $m Toxicology and applied pharmacology $n Toxicol Appl Pharmacol $x MED00010691
GRA    __
$a R01 CA103314 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...